Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, added on X:
”Beyond surgery in high-risk prostate cancer.
PROTEUS: adding apalutamide + hormone therapy around surgery improved 3-year freedom from recurrence: 63% vs 41%.
PROTEUS/STAMPEDE/ENZARAD: Same drug class, three different answers. Maybe the question is not ‘does it work’ but ‘for whom’.”
Title: Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy
Authors: Alberto Briganti, Thomas Steuber, Neal D. Shore, Martin Gleave, Alexander Kretschmer, Lisa Wetherhold, Eleni Efstathiou, David J. Cahn, Ronaldo Damião, Alexandre De La Taille, Seok-Soo Byun, Boris A. Hadaschik, Bernardo Herrera Imbroda, Álvaro Juárez Soto, Axel S. Merseburger, Giuseppe Simone, Brendan Rooney, Denis Mikerin, Zhuokai Li, Branko Miladinovic, Mary-Ellen Taplin
You can also read:
PROTEUS Trial the Day After: Practice-Changing or Premature Escalation?
